Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [6]. Core Insights - The company has over 40 listed products across various therapeutic areas, with core products like TPIAO and Mandi series expected to maintain steady growth. The research pipeline is rich, with several innovative drugs entering harvest periods, particularly SSGJ707 showing promising early clinical results [6][13]. - The company is well-positioned in the market with a diversified business layout and mature commercialization capabilities, driving stable growth of core products [7]. - Financial projections indicate a net profit of 2.33 billion, 2.61 billion, and 2.94 billion CNY for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.97, 1.09, and 1.23 CNY, suggesting a favorable valuation [9]. Summary by Sections 1. Core Products and Innovation Pipeline - The company has a strong focus on innovative drug development, with SSGJ707 (a PD-1/VEGF dual antibody) showing excellent early clinical data and potential for significant market impact [8][24]. - TPIAO, the company's flagship product, is the only commercialized rhTPO globally, with plans to expand its indications, including a recent approval for pediatric ITP [28][34]. 2. Financial Performance and Projections - The company reported a revenue of 9.11 billion CNY in 2024, reflecting a year-on-year growth of 16.5%. The net profit for the same year was approximately 2.09 billion CNY [9][21]. - The gross margin has been stable, with an increase from 80.98% in 2020 to 85.94% in 2024, indicating effective cost management [21]. 3. Market Position and Competitive Landscape - TPIAO has a market share of 66.6% in 2024, benefiting from its safety and efficacy profile, which allows it to replace traditional therapies [40][41]. - The company is actively collaborating with various pharmaceutical firms to enhance its product offerings and market reach, particularly in the oncology and hematology sectors [7][8]. 4. Research and Development Focus - The company has a comprehensive pipeline with 30 products under development, focusing on hematology, oncology, and autoimmune diseases, with several nearing NDA submission [25][24]. - The R&D expenses for 2024 were approximately 1.33 billion CNY, reflecting a commitment to innovation and development of high-value products [21].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the overall sentiment appears positive based on the performance metrics and growth outlook. Core Insights - The company reported a revenue of 2.073 billion yuan for 2024, representing a year-on-year increase of 30.9%, and a net profit attributable to shareholders of 356 million yuan, up 50.1% year-on-year [1] - The brand business is experiencing rapid growth, with significant contributions from the U.S. market, where revenue reached 1.251 billion yuan, reflecting a 69.0% increase year-on-year [2] - The gross margin for the company improved to 40.3%, with the brand business gross margin at 43.5%, indicating strong profitability [3] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 2.073 billion yuan, with a net profit of 356 million yuan, and an adjusted net profit of 383 million yuan [1] - The revenue for the second half of 2024 (Q2-Q4) was 1.570 billion yuan, showing a year-on-year growth of 21.6% [1] - The company expects revenues to grow to 2.711 billion yuan in 2025, with net profits projected at 428 million yuan [6] Business Segments - The brand business generated 1.861 billion yuan in revenue, a 34.8% increase year-on-year, while the ODM business brought in 213 million yuan, up 4.7% [2] - The brand business accounted for 89.7% of total revenue, an increase of 2.6 percentage points year-on-year [2] Profitability and Expenses - The company's gross margin improved to 40.3%, with the brand business gross margin at 43.5% [3] - Sales expenses increased due to higher e-commerce platform commissions and increased online marketing efforts, leading to a sales expense ratio of 18.1% [3] - The net profit margin for 2024 was 17.2%, reflecting an increase of 2.2 percentage points year-on-year [3] Future Outlook - The company is expected to continue its rapid revenue growth, with projections indicating a revenue increase of 31% in 2025 [6] - The focus will be on product development and expanding both online and offline sales channels, particularly in the U.S., China, Western Europe, and Japan [3][4]

(30%) (12%) 6% 24% 42% 60% 24/3/27 24/6/7 24/8/18 24/10/29 25/1/9 25/3/22 ◼ 股票数据 总股本/流通(亿股) 31.13/31.13 总市值/流通(亿港元) 467.52/467.52 12 个月内最高/最低价 (港元) 17.28/9 2025 年 03 月 27 日 公司点评 买入/维持 雅迪控股(01585) 目标价: 昨收盘:15.02 雅迪控股：2024H2 业绩短期承压，中高端+出海值得期待 ◼ 走势比较 相关研究报告 <<收入利润双位数增长，优化产品结 构和终端有望持续增厚业绩>>-- 2024-03-20 <<雅迪控股 23H1 点评：拓展价格带 推升销量，盈利压力逐步释放>>-- 2023-08-30 证券分析师：孟昕 E-MAIL：mengxin@tpyzq.com 分析师登记编号：S1190524020001 研究助理：赵梦菲 E-MAIL：zhaomf@tpyzq.com 一般证券业务登记编号：S1190124030006 研究助理：金桐羽 E-MAIL：jinty@tpyzq.com 一般证券业务登记编号：S1 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][9]. Core Insights - The company is reducing its reliance on a single IP and is expected to achieve strong growth through market penetration and international expansion [8][20]. - The company has demonstrated significant revenue growth, with a projected increase in revenue from 8.77 billion RMB in 2023 to 41.07 billion RMB in 2025, reflecting a growth rate of 83% [7][26]. - The company is expanding its IP portfolio and product offerings, with a notable increase in SKUs to 682 in 2024, enhancing its competitive edge [8][18]. Financial Data and Profit Forecast - Revenue projections for 2023 to 2027 are as follows: 8.77 billion RMB (2023), 22.41 billion RMB (2024), 41.07 billion RMB (2025), 61.82 billion RMB (2026), and 76.51 billion RMB (2027) [7][26]. - Adjusted net profit is expected to grow from 742.63 million RMB in 2023 to 1.09 billion RMB in 2025, with corresponding growth rates of 133.37% and 87.41% [7][26]. - The gross margin is projected to remain stable, with a slight increase from 47.33% in 2023 to 53.57% in 2025 [7][26]. Growth Drivers - The company is diversifying its IP portfolio, reducing the share of its main IP, Ultraman, from 57% in the first half of 2024 to 41% in the second half [15][11]. - The company is targeting lower-tier markets with a successful 9.9 RMB product series, which has shown strong sales and potential for further penetration [20][21]. - International expansion is a key focus, with overseas revenue expected to reach 353 million RMB in 2025, reflecting a growth rate of 450% [30][26]. Market Positioning - The company is leveraging its extensive sales network and product development capabilities to enhance its IP acquisition and product differentiation [8][18]. - The introduction of new IPs and products is anticipated to broaden the customer base, particularly among women and older demographics [20][21]. - The company is positioned to benefit from a growing demand for affordable and high-quality building toys, with a strong market presence in Southeast Asia and North America [21][26].

Investment Rating - The report maintains a "Buy" rating for the company [4][5] Core Insights - The company achieved steady growth in 2024, with revenue of 4.75 billion RMB, a year-on-year increase of 7.2%, and a net profit of 240 million RMB, up 23.5% year-on-year [1] - The company continues to deepen its global market expansion, with stable revenue growth across major segments [2] - The overseas market, particularly Iraq, showed strong performance, contributing significantly to future growth [3] Revenue and Profitability - In 2024, the oilfield management services segment generated revenue of 1.85 billion RMB, a 14.2% increase year-on-year [2] - The oilfield technical services segment reported revenue of 2.13 billion RMB, up 5.2% year-on-year [2] - The company’s comprehensive gross margin was 29.5%, a slight decrease of 0.3 percentage points year-on-year, while the net profit margin increased by 0.4 percentage points to 5.4% [1] Market Performance - Domestic market revenue was 1.66 billion RMB, down 4.8% year-on-year, while overseas market revenue reached 3.09 billion RMB, a 15.0% increase [3] - The Iraq market alone generated 2.6 billion RMB in revenue, reflecting a 17.7% year-on-year growth due to increased capital investment from major clients [3] Order Growth - The company secured new orders worth 3.21 billion RMB in the domestic market, a 22.5% increase year-on-year, and 5.01 billion RMB in the Iraq market, a significant 97.3% increase [3] - Overall, the company’s robust order book supports its future growth trajectory [3] Financial Forecast - The report projects a 10.8% and 15.7% increase in net profit for 2025 and 2026, respectively, with estimates of 360 million RMB and 460 million RMB [4] - Earnings per share (EPS) are forecasted to be 0.12 RMB for 2025, 0.15 RMB for 2026, and 0.19 RMB for 2027 [4]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [6]. Core Insights - The company has over 40 listed products across various therapeutic areas, with core products like TPIAO and Mandi series expected to maintain steady growth. The research pipeline is rich, with several innovative drugs entering harvest periods, particularly SSGJ707 showing promising early clinical results [6][13]. - The company is well-positioned in the market with a diversified business layout and mature commercialization capabilities, driving stable growth of core products [7]. - Financial projections estimate the company's net profit for 2025-2027 to be 2.328 billion, 2.612 billion, and 2.938 billion CNY, with corresponding EPS of 0.97, 1.09, and 1.23 CNY, indicating a favorable valuation trend [9]. Summary by Sections 1. Core Products and Innovation - The company has a strong portfolio with TPIAO as its leading product, projected to achieve a 20.4% year-on-year growth in 2024. The successful negotiation for continued pricing and the addition of new indications for TPIAO are expected to provide new growth opportunities [7][40]. - Mandi, the first OTC minoxidil in China, is anticipated to continue its growth trajectory, with revenue reaching 1.337 billion CNY in 2024 [7]. 2. Research and Development Pipeline - The company has a robust pipeline with 30 products under development, focusing on hematology, oncology, and autoimmune diseases. SSGJ707 has shown excellent early clinical data and is expected to be a significant product [8][24]. - The NDA for SSS06, a new generation long-acting erythropoietin, has been accepted, and several other products are in various clinical stages, indicating a strong potential for future revenue growth [8][25]. 3. Financial Performance and Projections - The company reported a revenue of 7.836 billion CNY in 2023, with a projected increase to 10.078 billion CNY in 2025, reflecting a compound annual growth rate of 10.7% [9]. - The gross margin is expected to remain stable around 84.2% for the next few years, with net profit margins improving to 26.6% by 2025 [9][21]. 4. Market Position and Competitive Landscape - TPIAO is the only commercialized rhTPO globally, with expanding indications and a significant market share of 66.6% in 2024. The product's safety and efficacy advantages position it favorably against competitors [34][40]. - The company has established collaborations with various pharmaceutical firms, enhancing its market presence and potential for revenue growth [7].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268.HK) [4] Core Views - WuXi AppTec reported strong annual performance for 2024, with revenue increasing by 91% year-on-year to 4.052 billion RMB and net profit attributable to shareholders rising by 277% to 1.070 billion RMB [1] - The company is experiencing robust growth in new projects and a diverse development in research projects, with 45 early discovery projects advancing to the iCMC stage and a total of 681 early discovery projects [1][2] - The company has a strong order backlog, with a total of 991 million USD in hand orders at the end of 2024, representing a 71% year-on-year increase [3] Summary by Sections Financial Performance - Revenue for 2024 reached 4.052 billion RMB, with a growth rate of 90.8% [4] - Adjusted net profit for 2024 was 1.174 billion RMB, reflecting a year-on-year increase of 185% [1] - Gross margin improved by 4.3 percentage points to 30.6%, while adjusted net profit margin increased by 7.3 percentage points to 26.4% [1] Business Development - The company signed 53 new comprehensive projects in 2024, including 9 backend production projects [1] - The production capacity at the Wuxi base is operating at high/full load, with a delivery success rate exceeding 99% [2] - The company plans to expand its production capacity significantly, with new lines expected to come online in 2025 and 2027 [2] Market Position - WuXi AppTec serves a growing client base, with 499 cumulative clients, including 13 of the top 20 global pharmaceutical companies [3] - The company anticipates continued growth in inquiries for iCMC stage projects, particularly in the U.S. market, which saw a 43% year-on-year increase in inquiries [3] Future Projections - Revenue projections for 2025, 2026, and 2027 are 5.554 billion RMB, 7.291 billion RMB, and 9.395 billion RMB, respectively, with expected growth rates of 37.1%, 31.3%, and 28.9% [4] - Net profit attributable to shareholders is projected to reach 1.342 billion RMB, 1.870 billion RMB, and 2.448 billion RMB for the same years, with growth rates of 25.4%, 39.4%, and 30.9% [4]

Investment Rating - The report maintains a "Buy-A" investment rating for the company, with a 6-month target price of HKD 30.50 per share, based on a PE ratio of 30 times for 2025 [5][7]. Core Insights - The company reported a revenue of CNY 18.675 billion for 2024, representing a year-on-year growth of 9.6%, with a net profit of CNY 3.945 billion, up 10.5% year-on-year [2][5]. - The non-COVID revenue grew by 13.1%, indicating a strong performance in clinical and commercial production services [2][3]. - The company expanded its project pipeline significantly, adding 151 new projects in 2024, bringing the total to 817 projects, which supports future revenue growth [3][4]. Revenue and Profit Summary - In 2024, the revenue breakdown includes CNY 7.062 billion from IND pre-services, CNY 3.816 billion from Phase I/II clinical development services, and CNY 7.485 billion from Phase III clinical development services and commercial production [2]. - The company expects net profits for 2025, 2026, and 2027 to be CNY 3.918 billion, CNY 4.547 billion, and CNY 5.332 billion, respectively, with growth rates of 16.75%, 16.05%, and 17.26% [5][12]. Business Model and Growth Drivers - The integrated CRDMO platform is enhancing the company's operational efficiency and driving steady business growth, with a significant reduction in delivery time from DNA to IND now at 9 months [4]. - The report highlights the potential for accelerated project delivery with 148 new development projects added in 2024, and a steady increase in production batches expected in 2025 [4][5]. Market Performance - The company's stock has shown strong performance with a relative return of 18.2% over the past month and 89.4% over the past year [8]. - The current stock price is HKD 27.75, which is below the target price, indicating potential upside for investors [7].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative return of over 20% within the next six months [8][16]. Core Insights - The company reported a revenue of 42.8 billion yuan for 2024, representing a year-on-year growth of 3.1%. Core operating profit reached 6.23 billion yuan, up 18.7% year-on-year, and net profit attributable to shareholders was 4.71 billion yuan, an increase of 4.6% [1]. - The company has initiated a franchise business, successfully launching 13 franchise restaurants in 2024, contributing 16.71 million yuan in revenue. Over 70% of franchise applications are from third-tier cities and below [4]. - The company has also launched the "Pomegranate Plan" to encourage the incubation and development of new restaurant brands, resulting in 11 new brands with a total of 74 stores, generating 480 million yuan in revenue, a year-on-year increase of 39.6% [4]. Financial Performance - In 2024, the company's restaurant system sales increased by 3% year-on-year, with same-store sales growing by 3.6% [2]. - The average table turnover rate for self-operated restaurants was 4.1 times per day, an increase of 0.3 times year-on-year [2]. - The overall average customer spending was 97.5 yuan, a decrease of 1.6% year-on-year, attributed to changes in the consumption structure [2]. Cost and Efficiency - The cost of raw materials accounted for 37.9% of revenue, down 3.0 percentage points year-on-year due to lower procurement prices. Employee costs increased to 33.0%, up 1.5 percentage points, reflecting higher wages and benefits [3]. - The company plans to distribute a final dividend of 0.507 HKD per share, alongside an interim dividend of 0.391 HKD, resulting in an overall dividend payout ratio of approximately 95% for 2024 [5]. Future Outlook - The company is expected to continue optimizing store operating efficiency and expanding its franchise business, with projected net profits for 2025-2027 at 5.3 billion, 5.86 billion, and 6.53 billion yuan respectively, corresponding to PE ratios of 18, 16, and 15 times [6].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 14.759 billion yuan for 2024, representing a year-on-year growth of 8.5%, while the adjusted net profit reached 624 million yuan, up 29.7% year-on-year [2] - The gross margin for 2024 was 25.4%, an increase of 0.7 percentage points year-on-year, driven by higher sales of proprietary and controlled brands, better procurement terms from suppliers, and a strategic reduction in low-margin wholesale services [3] - The company expanded its channel network, investing nearly 100 million yuan to support franchisee growth, resulting in a total of 6,874 service locations by the end of 2024, with over 90% of stores operating profitably [4] - The number of transaction users on the platform grew by 24.8% year-on-year, with the company also launching new services such as light beauty services and electric vehicle charging stations [5] Financial Summary - The company’s revenue for 2024 was 14.759 billion yuan, with a year-on-year growth of 8.5% [8] - The adjusted net profit for 2024 was 483.79 million yuan, showing a significant decline of 92.78% year-on-year [8] - The projected revenues for 2025, 2026, and 2027 are 16.256 billion yuan, 17.793 billion yuan, and 19.282 billion yuan, respectively, with expected growth rates of 10%, 9%, and 8% [6] - The adjusted net profit forecasts for 2025, 2026, and 2027 are 630.52 million yuan, 823.05 million yuan, and 1.031 billion yuan, respectively [6] - The earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 0.77 yuan, 1.00 yuan, and 1.26 yuan, respectively [6]